Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes - PubMed
4 days ago
- #GLP-1 receptor agonists
- #type 2 diabetes
- #rheumatoid arthritis
- Study evaluates GLP-1 RAs' impact on survival and renal outcomes in rheumatoid arthritis and type 2 diabetes patients.
- Retrospective cohort study with 4,607 patients per group comparing GLP-1 RAs vs. DPP-4is.
- GLP-1 RA use linked to 32% lower mortality, 11% fewer kidney events, and 8% fewer hospitalizations.
- No significant difference in major adverse cardiovascular events (MACE) between the two groups.
- Findings support GLP-1 RAs as a promising therapy for high-risk patients with rheumatoid arthritis and type 2 diabetes.